BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beta-Thalassemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Beta-Thalassemia\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07506863-10280@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07506863)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3\, Transfusion-Dependent Beta Tha
 lassemia.\nStudy: A Study to Investigate the Efficacy\, Pharmacokinetics\,
  and Safety of Mitapivat in Pediatric Participants With Transfusion-Depend
 ent Alpha- or Beta-Thalassemia (α- or β-TDT)\nEstimated primary completi
 on: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapi
 vat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07506863
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
